Charcot neuro-osteoarthropathy (CN), often called the Charcot foot, is one of the most consequential yet under-recognized complications of diabetes. It is a progressive condition in which bones and joints in an insensate foot fracture, dislocate, and collapse—frequently without the pain that would normally prompt a patient to seek care. Because the earliest phase can mimic a simple sprain, cellulitis, or gout, delayed diagnosis is common, and delay is precisely what leads to permanent deformity, ulceration, and amputation. Understanding how CN develops, how it is recognized, and how it is managed is central to preserving limbs in people living with diabetic neuropathy.
Why the Charcot Foot Develops
CN arises from the intersection of several diabetes-related processes. The essential prerequisite is peripheral neuropathy, which removes the protective sensation that normally guards the foot against injury. On this background, repetitive mechanical trauma—ordinary walking on a foot that cannot feel damage—combines with autonomic dysfunction that increases blood flow to bone and accelerates bone resorption. The result is a self-perpetuating cycle of inflammation and skeletal breakdown. A 2023 review in Cureus described this pathophysiology as multidimensional, linking peripheral neuropathy, repetitive trauma, and autonomic dysregulation, and noted that longer diabetes duration and poor glycemic control are among the factors that raise an individual’s risk.
Recognizing Active Charcot Early
The single most important principle in Charcot care is early suspicion. In the acute phase, the foot or ankle typically appears red, swollen, and warm, often with a temperature difference of several degrees compared with the opposite limb. Crucially, these signs occur in a patient with neuropathy and frequently with little or no pain, which is why the condition is so often mistaken for infection or an insect bite. Clinicians reviewing conservative management in Clinics in Podiatric Medicine and Surgery (2022) emphasized that a high index of suspicion should be maintained for any neuropathic patient presenting with erythema, edema, and warmth, and that immobilization should begin as soon as the diagnosis is suspected rather than after deformity has appeared.
The International Working Group on the Diabetic Foot (IWGDF) published its first dedicated guideline on active CN in 2023. Developed using GRADE methodology and a systematic review of the literature, the guideline underscores that diagnosis rests primarily on clinical findings supported by imaging. Plain radiographs may be normal early in the disease, so magnetic resonance imaging is valuable for detecting the bone-marrow edema and subtle fractures that precede visible collapse. Distinguishing CN from osteomyelitis remains a recurring diagnostic challenge that shapes treatment decisions.
Management: Offloading, Immobilization, and Time
The foundation of treatment for active CN is offloading and immobilization to protect the fragile skeleton while inflammation subsides. A total contact cast or equivalent non-removable device is widely regarded as the reference standard, and patients generally remain non–weight-bearing or protected until the affected bones and joints coalesce—a process that can take many months. As the conservative-management literature stresses, patient education and realistic expectations are essential, because premature return to unprotected walking is a leading cause of severe deformity, recurrent ulceration, and eventual amputation.
Pharmacologic agents such as bisphosphonates and calcitonin have been investigated as adjuncts intended to slow bone turnover, but the evidence base remains limited, and the IWGDF guideline does not endorse them as substitutes for offloading. When CN produces an unstable or severely deformed foot that cannot be accommodated in footwear or bracing, surgical reconstruction may be considered. Techniques described in the recent surgical literature range from internal plate fixation and intramedullary beaming to staged external fixation using computer-assisted hexapod frames for significant angular deformity. Such reconstruction is technically demanding and requires attention to vascular status, infection control, and soft-tissue coverage.
A Growing Clinical Burden
Epidemiologic data suggest that the clinical burden of CN is not receding. A 2024 analysis of Texas hospital discharge data published in Primary Care Diabetes found that age-standardized rates of diabetic CN rose across most years from 2006 to 2016, and that both major and minor amputations among patients with CN increased over the same period. The authors argued that these trends highlight an ongoing need for standardized strategies for diagnosis and management—reinforcing that earlier recognition and consistent offloading remain the most effective tools for preventing catastrophic outcomes.
Key Takeaways
Charcot neuro-osteoarthropathy is a limb-threatening complication that develops when neuropathy, repetitive trauma, and altered bone metabolism combine in the diabetic foot. Its hallmark early presentation—a warm, swollen, often painless foot in a neuropathic patient—demands immediate suspicion and prompt immobilization, because the window to prevent permanent deformity is narrow. Offloading with a total contact cast remains the cornerstone of active-phase care, imaging aids in distinguishing CN from infection, and surgery is reserved for unstable or severely deformed limbs. With rates of CN and associated amputations rising, timely recognition and disciplined offloading continue to offer the best protection against disability and limb loss.
References
Wukich DK, Schaper NC, Gooday C, et al. Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus (IWGDF 2023). Diabetes/Metabolism Research and Reviews. 2023;40(3):e3646.
Schweitzer M, Rockhill S. Conservative Management of Charcot Neuroarthropathy. Clinics in Podiatric Medicine and Surgery. 2022;39(4):585–594.
Bansod H, Wanjari A, Dumbhare O. A Review on Relationship Between Charcot Neuroarthropathy and Diabetic Patients. Cureus. 2023;15(12):e50988.
Cole KA, Jupiter DC. Charcot neuroarthropathy in diabetic patients in Texas. Primary Care Diabetes. 2024;18(5):533–538.
Spingola HD, Martucci J, DiDomenico LA. Plate Fixation in Midfoot and Ankle Charcot Neuroarthropathy. Clinics in Podiatric Medicine and Surgery. 2022;39(4):675–693.
Comments
